SCHEMBL2199661

SCHEMBL2199661

COC(=O)c1cc(OCc2ccc(OC)cc2)ccc1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.53
RAB9A P51151 5/20 0.53
SMPD1 P17405 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
POLB P06746 1/20 0.52
MAPT P10636 4/20 0.52
ALDH1A1 P00352 1/20 0.52
HTT P42858 1/20 0.52
FFAR1 O14842 2/20 0.51
MAOB P27338 3/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
CASP3 P42574 1/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
MAOA P21397 1/20 0.49
KDM4E B2RXH2 2/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2C19 P33261 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7765941 0.88 SMPD1 (0.56) NPC1RAB9ASMPD1SMN1; SMN2POLB
SCHEMBL4212043 0.84 MAOB (0.58) NPC1RAB9ASMPD1SMN1; SMN2POLB
SCHEMBL29502160 0.83 KDM4E (0.62) NPC1RAB9ASMN1; SMN2POLBMAPT
SCHEMBL146258 0.83 KDM4E (0.62) NPC1RAB9ASMN1; SMN2POLBMAPT
SCHEMBL29032389 0.83 SMPD1 (0.53) NPC1RAB9ASMPD1SMN1; SMN2POLB
SCHEMBL15831652 0.82 ALDH1A1 (0.56) NPC1RAB9AMAPTALDH1A1HTT
SCHEMBL14893940 0.82 MAOB (0.63) NPC1RAB9ASMPD1SMN1; SMN2POLB
SCHEMBL13162401 0.80 TDP1 (0.49) NPC1RAB9ASMN1; SMN2POLBMAPT
SCHEMBL7907439 0.80 MAOB (0.56) NPC1RAB9ASMPD1SMN1; SMN2POLB
SCHEMBL9923803 0.79 NPC1 (0.45) NPC1RAB9AMAPTMAOBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1658263-B9 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2011-11-09 EP disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
EP-1658263-B1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2010-06-02 EP disclosed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US disclosed
EP-1658263-A1 NOVEL AMINOBENZOPHENONE COMPOUNDS Leo Pharma A/S (DK) 2006-05-24 EP disclosed
WO-2005009940-A1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA A/S (DK) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166990-A1 Novel aminobenzophenone compounds NFKBIA, UACA, ALDH7A1 NPC1 2170/4885RAB9A 1123/4885SMPD1 4133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.